Rare cell multistage separation microfluidic device integrated with inertial and deterministic lateral displacement technology

Abstract

The invention discloses a rare cell multistage separation microfluidic device integrated with an inertial and deterministic lateral displacement technology. One end of the integrated device is provided with a sample inlet; the bottom of the sample inlet is communicated to a spiral runner; the other end of the spiral runner is communicated with a sudden expansion structure; the other end of the sudden expansion structure is divided into a first branch runner and a deterministic lateral displacement runner; the tail end of the first branch runner is provided with a hemocyte outlet; the other endof the deterministic lateral displacement runner is divided into a second branch runner and a third branch runner; the tail end of the second branch runner is provided with a residual hemocyte outlet; and the tail end of the third branch runner is provided with a rare cell outlet. By integrating two stages of runners: the inertial spiral runner and the deterministic lateral displacement runner, the rare cell multistage separation microfluidic device fully makes use of the high flux advantage of an inertial spiral and the high accuracy advantage of a deterministic lateral displacement; furthermore, the device is ingeniously integrated with a simple structure basis to realize high flux and high purity sorting of rare cancer cells; and the shortcoming that an existing sorting chip hardly simultaneously realizes the high flux and high purity sorting in only accordance with a certain single technology is overcome.

Description

technical field [0001] The patent of the present invention belongs to the multi-stage sorting microfluidic device technology, and in particular relates to a microfluidic device for high-throughput and high-purity sorting of rare cell particles. Background technique [0002] Circulating tumor cells (CTCs), as seeds entering the human peripheral blood circulation, are clinically considered to be an early sign of tumor metastasis, and the detection of circulating tumor cells in blood is of great significance for the early diagnosis of cancer. The biggest challenge in the detection of CTCs is that their number is extremely rare. Usually, their ratio to normal human blood cells is only about 1:10. 9 , or only 1-100 CTCs in 1 mL of blood. Therefore, how to efficiently and accurately remove background blood cells from whole blood and capture rare circulating tumor cells is an important prerequisite for subsequent detection and analysis. Microfluidics technology, which emerged in ...

AI Technical Summary

Problems solved by technology

[0003]Although the active and passive separation technologies have made considerable progress in recent years, there are still three important indicators of purity, recovery and throughput. Their respective deficiencies, especially considering that there is generally a mutual game relationship between the three, such as the increase in flux will lead to the decrease in purity, and the recovery rate is often sacrificed in order to pursue high purity, etc., it is difficult for a single separation technology to satisfy CTCs at the same time. High-throughput, high-purity, high-recovery separation requirements

Images